616-06-8

Basic information

• Product Name: DL-Norleucine
• Synonyms: (+/-)-2-AMINOCAPROIC ACID;2-AMINOHEXANOIC ACID;CH3-(CH2)3-CH(NH2)-COOH;DL-NORLEUCINE;DL-ALPHA-AMINO-N-CAPROIC ACID;DL-2-AMINO-CAPROIC ACID;DL-2-AMINOHEXANOIC ACID;DL-2-AMINO-N-HEXANOIC ACID
• CAS NO: 616-06-8
• Molecular Formula: C₆H₁₃NO₂
• Molecular Weight: 131.17
• EINECS: 210-462-7
• Product Categories: Amino Acids;Unusual Amino Acids;Amino Acid Derivatives
• Mol File: 616-06-8.mol

Chemical Properties

• Melting Point: >300 °C(lit.)
• Boiling Point: 234 °C at 760 mmHg
• Flash Point: 95.3 °C
• Appearance: white to off-white crystalline powder
• Density: 1.1720
• Refractive Index: 1.4630 (estimate)
• Storage Temp.: Store at RT.
• Solubility: 11.49 g/L (25°C)
• PKA: pK1:2.335(+1);pK2:9.834(0) (25°C)
• Water Solubility: 11.49 g/L (25 ºC)
• Merck: 14,6706
• BRN: 1721748
• CAS DataBase Reference: DL-Norleucine(CAS DataBase Reference)
• NIST Chemistry Reference: DL-Norleucine(616-06-8)
• EPA Substance Registry System: DL-Norleucine(616-06-8)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• TSCA: Yes
• Hazardous Substances Data: 616-06-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
DL-Norleucine is used as an intermediate in the synthesis of pharmaceutical compounds for various therapeutic applications.
Used in Nutritional Supplements:
DL-Norleucine is used as a nutritional supplement to support muscle growth and recovery, as well as to enhance athletic performance.
Used in Research and Development:
DL-Norleucine is used as a research compound for studying the properties and functions of amino acids in biological systems.
Used in Food and Beverage Industry:
DL-Norleucine is used as a flavor enhancer and a building block for the synthesis of other amino acids in the food and beverage industry.

Biochem/physiol Actions

DL-Norleucine is a nonsulfur analogue of methionine that stimulates synthesis of cephalosporin C.

Purification Methods

Crystallise norleucine from water or aqueous MeOH. [Huffman & Ingersoll JAm Chem Soc 73 3366 1951, Beilstein 4 III 1386, 4 IV 2628.]

InChI:InChI=1/C6H13NO2/c1-2-3-4-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)

Upstream product

• 616-05-7 2-bromohexanoic acid 
• 99356-86-2 α-cyanocaproic acid 
• 92383-45-4 2-ethoxyimino-hexanoic acid 
• 534-59-8 n-butylmalonic acid 
• 855913-27-8 2-cyano-hexanoic acid hydrazide 
• 7522-01-2 2-acetylamino-2-cyano-hexanoic acid ethyl ester 
• 623-11-0 1-methyl-4-nitrosobenzene 
• 99190-13-3 butyl-formylamino-malonic acid dimethyl ester 
• 62183-10-2 acetylamino-butyl-malonic acid diethyl ester 
• 50706-05-3 2-phenylhydrazono-hexanoic acid 
• 109-65-9 1-bromo-butane 
• 69555-14-2 ethyl N-diphenylmethylene glycine 
• 84713-70-2 [(4-chloro-benzylidene)-amino]-acetic acid ethyl ester 
• 15911-73-6 tert-Butyl 2-aminohexanoate 

Downstream Products

• 29774-91-2 4-butyl-oxazolidine-2,5-dione 
• 4702-12-9 2-(1,3-dioxoisoindolin-2-yl)hexanoic acid 
• 118659-59-9 2-formamidohexanoic acid 
• 7477-48-7 N-(quinoline-2-carbonyl)-DL-norleucine 
• 455-60-7 DL-Norleucin-N-trifluoracetat 
• 37525-99-8 N-(N-benzoyl-glycyl)-norleucine 
• 55513-00-3 N-carbamoyl-D,L-norleucine 
• 110-62-3 pentanal 
• 5665-74-7 2-amino-1-hexanol 
• 15027-13-1 N-benzyloxycarbonylnorleucine 
• 7682-16-8 N-acetylnorleucine 
• 30057-76-2 3-acetamidoheptan-2-one 
• 530-36-9 erythro-2-amino-1,2-diphenylethanol 
• 530-36-9 threo-1,2-diphenyl-2-aminoethan-1-ol 

Relevant articles and documents

CuFe2O4@PDA magnetic nanomaterials with a core-shell structure: Synthesis and catalytic application in the degradation of methylene blue in water

In this paper, core-shell polydopamine (PDA)-encapsulated CuFe2O4 (CuFe2O4@PDA) magnetic nanoparticles (MNPs) were synthesized through in situ self-polymerization for the first time. The size of the core-shell product can be controlled by tuning the dopamine monomer concentration. The formation of a PDA layer effectively enhanced the catalytic performance and provided a large specific surface area which offered more active sites for the effective interaction. The as-synthesized CuFe2O4@PDA MNPs were characterized and their catalytic activity was evaluated using the degradation of methylene blue (MB) in the presence of H2O2 as a model reaction. The experimental results showed that MB could be degraded efficiently using CuFe2O4@PDA MNPs as a catalyst. Under the optimized conditions, the degradation efficiency of MB was above 97%. Furthermore, a possible reaction mechanism was discussed. Finally, the catalyst was used for effective degradation of MB in a Yellow River water sample, which indicates its potential for practical applications in water pollutant removal and environmental remediation.

FUNCTIONALIZED FLUORINE CONTAINING PHTHALOCYANINE MOLECULES

Functionalized fluorine containing phthalocyanine molecules, methods of making, and methods of use in diagnostic applications and disease treatment are disclosed herein. In some embodiments, the fluorine containing phthalocyanine molecules are functionalized with a reactive functional group or at least one cancer-targeting ligand (CTL). The CTL can facilitate more efficient binding and/or internalization to a cancer cell than to a healthy cell. The CTL can inhibit expression of oncoprotein in some embodiments. The pthalocyanine moiety can be used in diagnostic applications, such as fluorescence labeling of a cancer cell, and/or treatment applications, such as catalyzing formation of a reactive oxygen species (ROS) which can contribute to cell death of a cancer cell.

Biocatalytic asymmetric synthesis of unnatural amino acids through the cascade transfer of amino groups from primary amines onto keto acids

Flee to the hills: An unfavorable equilibrium in the amino group transfer between amino acids and keto acids catalyzed by α-transaminases was successfully overcome by coupling with a ω-transaminase reaction as an equilibrium shifter, leading to efficient asymmetric synthesis of diverse unnatural amino acids, including L-tert-leucine and D-phenylglycine. Copyright

Compositions and Methods for Binding Lysophosphatidic Acid

Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described.

Growth Hormone Secretagogue Receptor 1A Ligands

The present invention relates to new growth hormone secretagogue receptor 1A (GHS-R 1A) ligands, and pharmaceutical compositions comprising any of the new GHS-R1 A ligands. The ligands are suitable for a wide range of applications, and thus the present invention also relates to use of the GHS-R1 A ligands according to the present invention in the manufacture of a medicament for the treatment of an individual in need thereof. In another aspect, the present invention relates to a method of treatment of an individual in need thereof, comprising administering to said individual one or more of the GHS-R1A ligands disclosed herein, such as e.g. for treatment of cancer cachexia.

Process for producing beta-1, 3-n-acetylglucosamine transferase and n-acetylglucosamine- containing composite saccharide

The present invention can provide a process for producing a protein having β1,3-N-acetylglucosaminyltransferase activity using a transformant comprising a DNA encoding a protein having β1,3-N-acetylglucosaminyltransferase activity derived from a microorganism belonging to the genus Pasteurella and a process for producing an N-acetylglucosamine-containing complex carbohydrate using a transformant capable of producing a protein having β1,3-N-acetylglucosaminyltransferase activity derived from a microorganism.

METHOD OF SEARCHING SUBSTANE HAVING ANTIDIABETIC ACTIVITY

The present invention provides a screening method of a substance which inhibits binding of a condensed purine derivative to a pancreatic β cell or a treated product of the cell, a substance which inhibits binding of a condensed purine derivative to a protein capable of the condensed purine derivative, and a substance which inhibits the expression or enzymatic activity of a protein capable of a condensed purine derivative, which comprises using the condensed purine derivative and a pancreatic β cell or a treated product of the cell or a protein capable of binding to the condensed purine derivative.

Process for producing alpha 2,3/ alpha 2,8-sialyltransferase and sialic acid-containing complex sugar

The present invention can provide a process for producing a protein having α2,3/α2,8-sialyltransferase activity using a transformant comprising a DNA encoding a protein having α2,3/α2,8-sialyltransferase activity derived from a microorganism belonging to the genus Pasteurella and a process for producing a sialic acid-containing complex carbohydrate using a transformant capable of producing a protein having α2,3/α2,8-sialyltransferase activity derived from a microorganism.

Beta1, 3-galactose transferase and dna encoding the enzyme

The present invention provides a protein having β1,3-galactosyltransferase activity, a DNA encoding the protein, a transformant comprising the DNA, a process for producing the protein using the transformant, and a process for producing a galactose-containing complex carbohydrate using the transformant.

Process for producing alpha1,4-galactosyltransferase and galactose-containing complex sugar

The present invention can provide a process for producing a protein having α1.4-galactosyltransferase activity using a transformant comprising a DNA encoding a protein having α1.4-galactosyltransferase activity derived from a microorganism belonging to the genus Pasteurella and a process for producing a galactose-containing complex carbohydrate using a transformant capable of producing a protein having α1,4-galactosyltransferase activity derived from a microorganism.